RT Journal Article
SR Electronic
T1 Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.09.21260266
DO 10.1101/2021.07.09.21260266
A1 Datta, Pratik
A1 Ukey, Rahul
A1 Bruiners, Natalie
A1 Honnen, William
A1 Carayannopoulos, Mary O.
A1 Reichman, Charles
A1 Choudhary, Alok
A1 Onyuka, Alberta
A1 Handler, Deborah
A1 Guerrini, Valentina
A1 Mishra, Pankaj K.
A1 Dewald, Hannah K.
A1 Lardizabal, Alfred
A1 Lederer, Leeba
A1 Leiser, Aliza L.
A1 Hussain, Sabiha
A1 Jagpal, Sugeet K.
A1 Radbel, Jared
A1 Bhowmick, Tanaya
A1 Horton, Daniel B.
A1 Barrett, Emily S.
A1 Xie, Yingda L.
A1 Fitzgerald-Bocarsly, Patricia
A1 Weiss, Stanley H.
A1 Woortman, Melissa
A1 Parmar, Heta
A1 Roy, Jason
A1 Dominguez-Bello, Maria Gloria
A1 Blaser, Martin J.
A1 Carson, Jeffrey L.
A1 Panettieri, Reynold A.
A1 Libutti, Steven K.
A1 Raymond, Henry F.
A1 Pinter, Abraham
A1 Gennaro, Maria Laura
YR 2021
UL http://medrxiv.org/content/early/2021/07/14/2021.07.09.21260266.abstract
AB Monitoring the burden and spread of infection with the new coronavirus SARS-CoV-2, whether within small communities or in large geographical settings, is of paramount importance for public health purposes. Serology, which detects the host antibody response to the infection, is the most appropriate tool for this task, since virus-derived markers are most reliably detected during the acute phase of infection. Here we show that our ELISA protocol, which is based on antibody binding to the Receptor Binding Domain (RBD) of the S1 subunit of the viral Spike protein expressed as a novel fusion protein, detects antibody responses to SARS-CoV-2 infection and COVID-19 vaccination.We also show that our ELISA is accurate and versatile. It compares favorably with commercial assays widely used in clinical practice to determine exposure to SARS-CoV-2. Moreover, our protocol accommodates use of various blood- and non-blood-derived biospecimens, such as breast milk, as well as dried blood obtained with microsampling cartridges that are appropriate for remote collection. As a result, our RBD-based ELISA protocols are well suited for seroepidemiology and other large-scale studies requiring parsimonious sample collection outside of healthcare settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by NIH grants R01 HL149450, R01 HL149450-S1, U01 AI122285-S1, P30 ES005022, K23 AR070286, and UL1 TR003017.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Rutgers Institutional Review Board. All approved protocols are listed in methods section.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data will be provided on request.